› 3pp0

X-ray diffraction
2.25Å resolution

Crystal Structure of the Kinase domain of Human HER2 (erbB2).

Released:
DOI: 10.2210/pdb3pp0/pdb
PDB entry 3pp0 coloured by chain, front view.
PDB entry 3pp0 coloured by chain, side view.
PDB entry 3pp0 coloured by chain, top view.
Source organism: Homo sapiens
Primary publication:
Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein.
Aertgeerts K, Skene R, Yano J, Sang BC, Zou H, Snell G, Jennings A, Iwamoto K, Habuka N, Hirokawa A, Ishikawa T, Tanaka T, Miki H, Ohta Y, Sogabe S
J Biol Chem 286 18756-65 (2011)
PMID: 21454582

Function and Biology Details

Reaction catalysed: 
ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate
Biochemical function:
Biological process:
Cellular component:
  • not assigned
Sequence domains:

Structure analysis Details

Assembly composition:
monomeric (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-138062 (preferred)
Entry contents:
1 distinct polypeptide molecule
Macromolecule:
Receptor tyrosine-protein kinase erbB-2 Chains: A, B
Molecule details ›
Chains: A, B
Length: 338 amino acids
Theoretical weight: 38.23 KDa
Source organism: Homo sapiens
Expression system: Antheraea
UniProt:
  • Canonical: P04626 (Residues: 703-1047; Coverage: 27%)
Gene names: ERBB2, HER2, MLN19, NEU, NGL
Sequence domains: Protein tyrosine and serine/threonine kinase
Structure domains:

Ligands and Environments

1 bound ligand:
Ligand 03Q 2 x 03Q
No modified residues

Experiments and Validation Details

Entry percentile scores
X-ray source: ALS BEAMLINE 5.0.3
Spacegroup: P212121
Unit cell:
a: 48.705Å b: 78.951Å c: 152.675Å
α: 90° β: 90° γ: 90°
R-values:
R R work R free
0.189 0.185 0.26
Expression system: Antheraea

Quick links

Citations

17 review citations

The structural basis for control of eukaryotic protein kinases.
Endicott et al. (2012)
16 more

115 mentions without citation

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer.
Collins et al. (2019)
114 more